127
Participants
Start Date
November 15, 2023
Primary Completion Date
July 24, 2025
Study Completion Date
July 1, 2026
Satralizumab
Satralizumab will be administered by SC injection.
Placebo
Placebo will be administered by SC injection
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat
Seoul National University Bundang Hospital, Seongnam-si
Hospital Universitario Virgen de las Nieves, Granada
Scheie Eye Institute, Philadelphia
Hospital Ramon y Cajal, Madrid
Hospital Universitario Clínico San Carlos, Madrid
Vanderbilt Eye Institute, Nashville
Hospital Universitario Virgen de la Macarena, Seville
CHU Nantes - Hôtel Dieu, Nantes
Hospital Universitario la Fe: Servicio de Oftalmologia, Valencia
University of Illinois Eye and Ear Infirmary, Chicago
CHNO Hopital des Quinze Vingts, Paris
Fondation Rothschild, Paris
Retina Consultants of Texas, San Antonio
Plastics-Orbit-Neuro, San Diego
Peking Union Medical College Hospital, Beijing
Peking University Third Hospital, Beijing
Beijing Hospital of Ministry of Health, Beijing
Beijing Tongren Hospital, Capital Medical University, Beijing
Xi'an Fourth Hospital, Xi'an
Rabin MC, Petah Tikva
Hadassah MC, Jerusalem
Connecticut Eye Consultants, P.C., Danbury
University of Alberta, Edmonton
Sheba medical center, Ramat Gan
Toronto Retina Institute, Toronto
Universite de Montreal - Hopital Maisonneuve-Rosemont, Montreal
Specjalistyczny O?rodek Okulistyczny Oculomedica, Bydgoszcz
Optimum Profesorskie Centrum Okulistyki, Gdansk
AIBILI - Association for Innovation and Biomedical Research on Light, Coimbra
Severance Hospital, Yonsei University Health System, Seoul
Chung-Ang University Hospital, Seoul
Samsung Medical Center, Seoul
Hospital Universitario Vall d Hebron, Barcelona
Sussex Eye Hospital, Brighton
Bristol Eye Hospital, Bristol
Gartnavel General Hospital, Glasgow
St James University Hospital, Leeds
Royal Liverpool University Hospital, Liverpool
Moorfields Eye Hospital NHS Foundation Trust, London
Maidstone Hospital, Maidstone, Kent
Hoffmann-La Roche
INDUSTRY